VERARD
LOE Approachingverard
NDAUNKNOWNUNKNOWN
Approved
Aug 1939
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERARD is a legacy NDA-approved pharmaceutical product first approved in 1939 with an unknown mechanism of action, route, and dosage form. Limited clinical data is available in current records, suggesting this is a historical or discontinued product. The drug's original indications and patient population are not documented in available data.
LOE Approaching
With competitive pressure at 30% and LOE approaching, this product likely operates in a mature, fragmented market with minimal commercial team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VERARD shows zero linked job openings and minimal career growth potential given its LOE status and lack of competitive differentiation. Roles supporting this product are likely administrative, compliance-focused, or transition-oriented rather than career-advancing.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.